Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Cervical Cancer

Therapeutic area intelligence for Cervical Cancer with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
10
Catalysts
0
Companies
1

Companies

oncology pharmaceutical companies →

Assets

Bhutan →
DSG2 →
HPV →
IAP →
Phase →
University →

Recent signals(10)

StrategyJuly 31, 2026

HPV Vaccine Hesitancy Among Female Students in China Increases Despite Improved Knowledge

HPV vaccine hesitancy among female university students in China rose from 8.8% to 21.6% between 2022 and 2025, despite improved knowledge.

StrategyJuly 31, 2026

HPV Vaccination Challenges and Strategies in WHO South-East Asia Region Identified

The review identifies uneven HPV vaccination coverage across SEAR countries, with significant barriers to implementation.

ClinicalJuly 14, 2026

Study on Quality of Life Recovery in Cervical Cancer Patients Post-Radiotherapy

A longitudinal observational study is assessing Quality of Life recovery in cervical cancer patients after radiotherapy.

StrategyJuly 12, 2026

HPV Vaccination Shows Moderate Effectiveness in Women Aged 18-45 in China

A study found that HPV vaccination provides moderate protection against high-risk HPV DNA positivity in women aged 18-45 in China, with effectiveness increasing over time since vaccination.

ClinicalJuly 10, 2026

Phase II Trial of HAL-PDT vs Surgery for High-Grade Squamous Intraepithelial Lesions

A Phase II trial is evaluating hexaminolevulinate photodynamic therapy (HAL-PDT) against immediate surgery for HSIL.

ClinicalJuly 7, 2026

TGFA identified as key regulator in cervical cancer progression via DSG2 interaction

TGFA promotes cervical cancer progression by interacting with DSG2, enhancing cell proliferation and metastasis.

ClinicalJuly 1, 2026

University of Florida Tests PINPOINT Intervention for Cervical Cancer Prevention

The University of Florida is adapting and testing the PINPOINT intervention to improve cervical cancer prevention among high-risk patients.

ClinicalJune 25, 2026

Study Identifies Biomarkers for Immunotherapy Response in Advanced Cervical Cancer

The study found that baseline CD4+ T-cell percentage and post-treatment levels of CA125/SCCA, CD8+ T-cells, and PD-1 expression are significantly associated with immunotherapy response in advanced cervical cancer.

ClinicalJune 23, 2026

IAP Overexpression May Predict Recurrence in Locally Advanced Cervical Cancer

The study investigates the prognostic role of IAP overexpression on recurrence rates in cervical cancer patients treated with radio-chemotherapy.

StrategyJune 20, 2026

HPV Vaccination Linked to Decline in High-Grade CIN Consultations in Brazil

The introduction of HPV vaccination in Brazil is associated with a significant decline in outpatient consultations for high-grade cervical intraepithelial neoplasia among adolescents.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Cervical Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.